High risk percutaneous coronary interventions—significance of left ventricular assist device for clinical practice
Cohen et al. have published the article (1), analyzing the use percutaneous left ventricular assist device (PLVAD) to support high risk percutaneous coronary intervention (HRPCI). The authors performed retrospective observational analysis of 339 patients included in the USpella registry, who were supported for HRPCI with a micro-axial rotational pump (Impella 2.5). There were patients that have met eligibility for the Impella arm of the PROTECT II trial (2). In-hospital outcomes of the USpella registry patients were compared with the results of 216 patients treated in the Impella arm of PROTECT II randomized trial. The authors concluded that despite the higher risk of registry patients, clinical outcomes appeared to be favorable and consistent compared with the randomized trial.